Back to Journals » Clinical Ophthalmology » Volume 15

Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy

Authors Maurya RP, Prajapat MK, Singh VP, Roy M, Todi R, Bosak S, Singh SK, Chaudhary S, Kumar A, Morekar SR

Received 24 October 2020

Accepted for publication 31 December 2020

Published 26 February 2021 Volume 2021:15 Pages 871—879


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser

Rajendra Prakash Maurya,1 Manish Kumar Prajapat,2 Virendra Pratap Singh,1 Meghna Roy,1 Ravina Todi,1 Sanjay Bosak,1 Sunit Kumar Singh,3 Sunil Chaudhary,4 Anil Kumar,5 Sunil R Morekar6

1Regional Institute of Ophthalmology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India; 2Mahamaya Rajkiya Allopathic Medical College, Ambedkar Nagar, UP, India; 3Department of Molecular Biology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India; 4Department of Radiotherapy and Radiation Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India; 5Department of Statistics, Faculty of Science & Technology, Mahatma Gandhi Kashi Vidyapith, Varanasi, Uttar Pradesh, India; 6Apollo Specialty Hospital, Navi Mumbai, India

Correspondence: Rajendra Prakash Maurya Email [email protected]

Purpose: To study the level of serum malondialdehyde (MDA), a biomarker of oxidative stress before and after chemotherapy in various ocular malignancies and to correlate its significance with clinicopathological parameters.
Methods: Thirty two histopathologically confirmed cases of primary ocular malignancies were included in this longitudinal cohort study. Detailed clinicopathological assessment was done. Analysis of serum MDA level in the patient before and after chemotherapy was measured and its prognostic significance was analyzed.
Results: Maximum cases were of eyelid malignancy (n=18, 56.2%) followed by retinoblastoma (18.8%) and OSSN (6, 18.8%). About 43.75% patients were in the advanced-stage. The tumor was histopathologically well-differentiated in 20 (62.5%) cases. Most common malignancy was sebaceous gland carcinoma of the eyelid (n=10,31.25%). Serum MDA level in patients were significantly higher than controls [5.5712± 0.32779 vs 2.5531± 0.08056 nmol/mL, p< 0.001]. Level was significantly reduced after chemotherapy (4.5146± 0.23209 nmol/mL). Serum MDA was maximum in cases of rhabdomyosarcoma (5.9450± 0.23335 nmol/mL) and retinoblastoma (5.7433± 0.14334 nmol/mL). It was minimum in basal cell carcinoma (5.3775± 0.17746 nmol/mL). Pre chemotherapy serum MDA level was significantly higher in patients having larger tumor (> 20mm, p< 0.001) and having lymph node metastasis than those without lymph node metastasis [5.8350± 0.17113 vs 5.4833± 0.32193 nmol/mL, p< 0.006]. No significant difference was observed in post chemotherapy serum MDA level as for as size of tumor (p=0.947) and histopathological differentiation (p=0.109) was concerned.
Conclusion: The serum MDA level is a potential biomarker in primary ocular carcinoma to assess oxidative stress and its impact on response to chemotherapy.

Keywords: malondialdehyde, chemotherapy, malignancy, oxidative stress, biomarker

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]